ATE299861T1 - Ppar-(gamma) agonisten zur behandlung von type ii diabetes - Google Patents

Ppar-(gamma) agonisten zur behandlung von type ii diabetes

Info

Publication number
ATE299861T1
ATE299861T1 AT00922297T AT00922297T ATE299861T1 AT E299861 T1 ATE299861 T1 AT E299861T1 AT 00922297 T AT00922297 T AT 00922297T AT 00922297 T AT00922297 T AT 00922297T AT E299861 T1 ATE299861 T1 AT E299861T1
Authority
AT
Austria
Prior art keywords
substituted
hydrogen
ppar
agonists
sulfonyl
Prior art date
Application number
AT00922297T
Other languages
English (en)
Inventor
Hartmuth C Kolb
Gerard Mcgeehan
Zhi-Cai Shi
Laxma Reddy Kolla
Cullen Cavallaro
Original Assignee
Coelacanth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coelacanth Corp filed Critical Coelacanth Corp
Application granted granted Critical
Publication of ATE299861T1 publication Critical patent/ATE299861T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00922297T 1999-04-19 2000-04-18 Ppar-(gamma) agonisten zur behandlung von type ii diabetes ATE299861T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13001199P 1999-04-19 1999-04-19
US17552800P 2000-01-11 2000-01-11
PCT/US2000/010416 WO2000063161A1 (en) 1999-04-19 2000-04-18 Ppar-(gamma) agonists as agents for the treatment of type ii diabetes

Publications (1)

Publication Number Publication Date
ATE299861T1 true ATE299861T1 (de) 2005-08-15

Family

ID=26828115

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00922297T ATE299861T1 (de) 1999-04-19 2000-04-18 Ppar-(gamma) agonisten zur behandlung von type ii diabetes

Country Status (7)

Country Link
EP (1) EP1173408B1 (de)
JP (1) JP2002542224A (de)
AT (1) ATE299861T1 (de)
AU (1) AU4250200A (de)
CA (1) CA2370742A1 (de)
DE (1) DE60021368T2 (de)
WO (1) WO2000063161A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
HU230253B1 (hu) 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
DK1355644T3 (da) 2001-01-26 2006-10-23 Schering Corp Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
EP1911462A3 (de) 2001-01-26 2011-11-30 Schering Corporation Zusammensetzungen enthaltend einen Sterolabsorptionshemmer
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
CN101444496B (zh) 2001-06-12 2011-04-13 维尔斯达医疗公司 用于治疗代谢失调的化合物
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
BR0314335A (pt) * 2002-09-05 2005-07-26 Novo Nordisk As Composto, uso do mesmo, composição farmacêutica, e métodos para o tratamento e/ou prevenção de condições mediadas por receptores nucleares, e de diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glicose, resistência à insulina ou obesidade
DE60332860D1 (de) * 2002-10-28 2010-07-15 High Point Pharmaceuticals Llc Neue verbindungen, die sich f r die behandlung von durch ppar vermittelten krankheiten eignen
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
FR2850969B1 (fr) * 2003-02-12 2005-03-25 Genfit S A Aminopropanediols acyles et analogues et leurs utilisations therapeutiques
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
EP3727424A4 (de) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. Konjugatbasierte systeme für kontrollierte insulinfreisetzung
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3118738B2 (ja) * 1992-12-22 2000-12-18 小野薬品工業株式会社 （チオ）ウレア誘導体
AU692438B2 (en) * 1993-03-29 1998-06-11 Astrazeneca Ab Heterocyclic derivatives as platelet aggregation inhibitors
EP0690847A1 (de) * 1993-03-29 1996-01-10 Zeneca Limited Heterozyklische derivate als plätchenaggregationsinhibitoren
CA2204616C (en) * 1995-09-18 2002-12-17 Ranjan Mukherjee Ppar gamma antagonists for treating obesity
JPH0987291A (ja) * 1995-09-26 1997-03-31 Wakamoto Pharmaceut Co Ltd 新規なアラニン誘導体
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
AU4050797A (en) * 1996-08-02 1998-02-25 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
AU8163398A (en) * 1997-06-23 1999-01-04 Pharmacia & Upjohn Company Inhibitors of alpha4beta1mediated cell adhesion
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
US6329372B1 (en) * 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
DE69919334T2 (de) * 1998-02-26 2005-08-04 Celltech Therapeutics Ltd., Slough Phenylalaninderivate als inhibitoren von alpha4 integrinen
TW591026B (en) * 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion

Also Published As

Publication number Publication date
AU4250200A (en) 2000-11-02
EP1173408A1 (de) 2002-01-23
CA2370742A1 (en) 2000-10-26
DE60021368T2 (de) 2006-07-27
DE60021368D1 (de) 2005-08-25
JP2002542224A (ja) 2002-12-10
WO2000063161A1 (en) 2000-10-26
EP1173408B1 (de) 2005-07-20

Similar Documents

Publication Publication Date Title
DE60021368D1 (de) Ppar-(gamma) agonisten zur behandlung von type ii diabetes
DE3069408D1 (en) 5-oxo- and 5-thioxoproline derivatives, process for their production and pharmaceutical compositions containing them
PL274751A1 (en) Method of obtaining novel derivatives of benzimidazoline-2-oxo-carboxylic acid
MY107740A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
YU32100A (sh) Derivati hidrosamske kiseline kao inhibitori matrične metaloproteaze (mmp)
ATE218141T1 (de) Erythromycin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
SE7906722L (sv) Merkaptoacylderivat av substituerade proliner
ATE435010T1 (de) Verwendung von retinoid rezeptor antagonisten für die behandlung von knochen und knorpel pathologien
DK0759919T3 (da) Azolidindioner som antihyperglykæmiske midler
DE3876813D1 (de) 3(2h)pyridazinon, verfahren zu dessen herstellung und dieses enthaltendes mittel gegen srs-a.
ATE110386T1 (de) Cephalosporinderivate, verfahren zu ihrer herstellung und antibakterielle präparate.
DE69309454D1 (de) Pyridincarboximidamide und deren anwendung
CA2179306A1 (en) Dopamine receptor ligands
FR2798126B1 (fr) Heteroaryloxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
ES455741A1 (es) Un procedimiento para la preparacion de nuevos derivados de 1,3-bencenodimetanol.
DK0573318T3 (da) 4-phenylcarbamoyl-3-isoxazolcarboxylsyreforbindelser, fremgangsmåde til deres fremstilling, farmaceutiske præparater med in
DK1205476T3 (da) Fremgangsmåde til syntese af N-(mercaptoacyl)-aminosyrederivater ud fra alfa-substituerede acrylsyrer
ATE2044T1 (de) 6h-1,2,4,6-thiatriazin-1,1-dioxide, herbizide, die diese verbindungen enthalten, ihre anwendung als herbizide und verfahren zu ihrer herstellung.
AR010205A1 (es) Un compuesto farmaceutico
ATE259817T1 (de) Herstellung von einem clavulansäuresalz
ATE149T1 (de) 2-(n-(2'-chlor-4'-methylthienyl-3')-n-(cyclopropyl- methyl)-amino)-imidazolin-(2), dessen saeureadditionssalze, dieses enthaltende arzneimittel und verfahren zu seiner herstellung.
ATE96026T1 (de) Verwendung heterozyklischer amide zur verhinderung der tumormetastasierung.
ATE266646T1 (de) Phenanthryl-piperazinyl-dicarbonsäure als selective nmda-rezeptor modulierende mittel
DE69904940D1 (de) 6-deoxy-erythromycin-derivate, ihrer herstellung, und ihrer verwendung als arzneimitteln
HUP0203921A2 (hu) Diazepin-karboxamid-származékok, eljárás a vegyületek előállítására, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties